Status:
Topic prioritisation
Technology type:
Medicine
Decision:
Not selected
Decision publication date:
04 November 2026
Prioritisation programme:
Medicines evaluation
Rationale:

The NICE-Wide Prioritisation Board met on 14 October 2026 and concluded that an evaluation would notbe appropriate for this product.

The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate this product is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate. Please see eligibility criteria within the prioritisation manual for further information.

ID number:
12208

Project Team

Project lead
Danielle Lees

Email enquiries

If you have any queries please email topic.selection@nice.org.uk

Timeline

Key events during the development of the guidance:

Date Update
28 October 2026 Topic prioritisation. Prioritisation Board decision
14 October 2026 Prioritisation board meeting
15 May 2025 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on how we select topics for development, please see our page about topic prioritisation